Alivus Life Sciences Q1 FY26 Revenue ₹6,018 Million, Non-GPL Business Up 14.5% YoY
The financial results indicate steady growth and profitability, which is likely to have a moderate impact on investor sentiment and the company's stock performance.
The announcement highlights revenue growth, strong EBITDA margins, and positive management commentary, indicating a positive outlook for the company.
* Alivus Life Sciences reported a revenue from operations of ₹6,018 million for Q1 FY26, a growth of 2.2% YoY. * EBITDA margins for the quarter were at 30.1%, up by 210 bps YoY. * Generic API revenues in Q1 FY26 grew by 3.0% YoY. * GPL business was at ₹1,526 million, a de-growth of 22.3% YoY, while Non-GPL business was at ₹4,492 million, up by 14.5% YoY. * The company generated a strong free cash flow of ₹1,000 million during Q1 FY26, leading to cash and cash equivalents of ₹6,604 million as of 30th June 2025. * Dr. Yasir Rawjee, Managing Director & Chief Executive Officer, commented that the company's performance was primarily driven by strong growth in the Non-GPL business, which expanded by 14.5% YoY, and that they remain confident of achieving high single-digit revenue growth in FY26, with stronger momentum expected in the second half. Margins are projected to remain healthy in the 28–30% range.
What to do with a filing like this
Alivus Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alivus Life Sciences Limited. Read the original for the full detail.